MedTrace Logo

NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry Eye

NCT00739349 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 132

Last updated 2016-06-06

No results posted yet for this study

Summary

Study is to assess the safety and efficacy of NOVA22007 0.05% and 0.1% Cyclosporine Ophthalmic Cationic Emulsions QD compared to vehicle for the treatment of the signs and symptoms of dry eye after a 3 month treatment period.

Conditions

  • Dry Eye

Interventions

DRUG

NOVA22007 ''Cyclosporine''

Cyclosporine 0.05% Ophthalmic Cationic Emulsions

DRUG

NOVA22007 ''Cyclosporine''

Cyclosporine 0.1% Ophthalmic Cationic Emulsions

DRUG

vehicle/placebo

vehicle/placebo

Sponsors & Collaborators

  • Santen SAS

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00739349 on ClinicalTrials.gov